이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Oncolytics Biotech 관리

관리 기준 확인 2/4

Oncolytics Biotech's CEO는 Matt Coffey, Jan2016 에 임명되었습니다 의 임기는 8.42 년입니다. 총 연간 보상은 CA$ 2.25M, 32.7% 로 구성됩니다. 32.7% 급여 및 67.3% 보너스(회사 주식 및 옵션 포함). 는 CA$ 134.71K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 134.71K. 경영진과 이사회의 평균 재임 기간은 각각 5.4 년과 6.6 년입니다.

주요 정보

Matt Coffey

최고 경영자

CA$2.2m

총 보상

CEO 급여 비율	32.7%
CEO 임기	8.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5.5yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31

CEO 보상 분석

Matt Coffey 의 보수는 Oncolytics Biotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CA$28m
Dec 31 2023	CA$2m	CA$735k	-CA$28m
Sep 30 2023	n/a	n/a	-CA$32m
Jun 30 2023	n/a	n/a	-CA$27m
Mar 31 2023	n/a	n/a	-CA$24m
Dec 31 2022	CA$1m	CA$654k	-CA$25m
Sep 30 2022	n/a	n/a	-CA$24m
Jun 30 2022	n/a	n/a	-CA$24m
Mar 31 2022	n/a	n/a	-CA$27m
Dec 31 2021	CA$2m	CA$637k	-CA$26m
Sep 30 2021	n/a	n/a	-CA$28m
Jun 30 2021	n/a	n/a	-CA$30m
Mar 31 2021	n/a	n/a	-CA$29m
Dec 31 2020	CA$1m	CA$541k	-CA$23m
Sep 30 2020	n/a	n/a	-CA$33m
Jun 30 2020	n/a	n/a	-CA$29m
Mar 31 2020	n/a	n/a	-CA$28m
Dec 31 2019	CA$965k	CA$525k	-CA$33m
Sep 30 2019	n/a	n/a	-CA$19m
Jun 30 2019	n/a	n/a	-CA$18m
Mar 31 2019	n/a	n/a	-CA$17m
Dec 31 2018	CA$2m	CA$475k	-CA$17m
Sep 30 2018	n/a	n/a	-CA$17m
Jun 30 2018	n/a	n/a	-CA$17m
Mar 31 2018	n/a	n/a	-CA$17m
Dec 31 2017	CA$726k	CA$430k	-CA$16m

보상 대 시장: Matt 의 총 보상 ($USD 1.64M )은 Canadian 시장( $USD 175.07K ).

보상과 수익: 회사가 수익성이 없는 동안 Matt 의 보상이 증가했습니다.

CEO

Matt Coffey

8.5yrs

테뉴어

CA$2,246,023

보상

Dr. Matthew C. Coffey, also known as Matt, Ph D., M.B.A., Co-founded Oncolytics Biotech Inc., and has been its Chief Executive Officer since 2016 and President since January 19, 2017. He has been a Directo...

리더십 팀

이름	위치	테뉴어	보상	소유권
Matthew Coffey	President	8.5yrs	CA$2.25m	0.13% CA$ 130.1k
Kirk Look	Chief Financial Officer	11.7yrs	CA$1.32m	1.17% CA$ 1.2m
Thomas Heineman	Chief Medical Officer	2.6yrs	CA$1.36m	0.68% CA$ 696.9k
Allison Hagerman	Vice President of Product Development	5.8yrs	CA$727.64k	0.68% CA$ 697.6k
Amy Levin	Vice President of Clinical Operations	1.5yrs	CA$683.55k	데이터 없음
Jon Patton	Director of Investor Relations & Communication	no data	데이터 없음	데이터 없음
John Lievonen	Consultant	5.2yrs	CA$25.98k	데이터 없음

5.5yrs

평균 재임 기간

경험이 풍부한 관리: ONC 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Matthew Coffey	President	13.2yrs	CA$2.25m	0.13% CA$ 130.1k
Bernd Seizinger	Independent Director	9.1yrs	CA$123.96k	0.50% CA$ 513.2k
James Parsons	Independent Director	2.1yrs	CA$116.36k	데이터 없음
Jonathan M. Rigby	Independent Director	1.9yrs	CA$107.40k	0.41% CA$ 425.1k
Wayne Pisano	Independent Chairman of the Board	11.2yrs	CA$165.01k	0.25% CA$ 256.4k
Angela Holtham	Independent Director	10.1yrs	CA$130.58k	0.17% CA$ 171.8k
Jean-Pierre Bizzari	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Padmanee Sharma	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Deborah Brown	Independent Director	6.7yrs	CA$124.95k	0.064% CA$ 66.1k
Martine Piccart	Member of Scientific Advisory Board	6.7yrs	데이터 없음	데이터 없음
Aleix Prat	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Vile	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음

6.7yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: ONC 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Oncolytics Biotech 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Independent Director recently bought CA$56k worth of stock

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Recent updates

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Oncolytics Biotech Inc. Announces Selection of Pelareorep for Inclusion as New Investigational Treatment in Precision Promise, an Innovative Adaptive Phase 3 Clinical Trial

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS

Consensus EPS estimates upgraded to CA$0.43 loss

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 20%

Price target decreased by 14% to CA$6.50

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting

Price target decreased to CA$6.21

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Independent Director recently bought CA$56k worth of stock

Consensus forecasts updated

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Oncolytics Biotech Inc. Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with Chimeric Antigen Receptor T Cell Therapy in Solid Tumors

Oncolytics Biotech Inc. Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer

No longer forecast to breakeven

Oncolytics Biotech® Inc. Provides Positive Safety Update on Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech Inc. Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

No longer forecast to breakeven

Oncolytics Biotech Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

No longer forecast to breakeven

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-Of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Oncolytics Biotech Inc., Annual General Meeting, May 07, 2021

Oncolytics Biotech Inc. Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Price target raised to CA$10.13

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New 90-day high: CA$3.40

Oncolytics Biotech Announces Positive Clinical Results against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Oncolytics Biotech® Inc. and Solti-Innovative Breast Cancer Research Announce the Publication of an Electronic Poster with Clinical Data from the Aware-1 Window-Of-Opportunity Breast Cancer Study At the Society for Immunotherapy of Cancer

Oncolytics Biotech Inc. Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

New 90-day high: CA$3.00

Oncolytics Biotech Inc. Appoints Richard Vile, Ph.D., to Its Scientific Advisory Board

New 90-day low - CA$2.14

Price target lowered to CA$7.51

New 90-day low - CA$2.46

CEO 보상 분석

CEO